

### INTRODUCTION

In 2013, Abreu et al identified loss-of function mutation in the MKRN3 gene of fifteen patients from five families with idiopathic central precocious puberty (iCPP), highlighting the implication of this maternally imprinted gene in this still poorly understood condition (4).

Since this study, other mutations have been described and now represent the most common genetic cause of iCPP.

#### AIM

The objective of the study was to document the clinical course of puberty in nine girls and one boy harbouring pathogenic MKRN3 variants.

## METHOD

Observational case series study of patients with iCPP and MKRN3 variants followed in our center.

<u>C. GERNAY<sup>1</sup>, C. BRACHET<sup>1</sup>, E. BOROS<sup>1</sup>, C. LIBIOULLE<sup>2</sup>, S. TENOUTASSE<sup>1</sup>, C. HEINRICHS<sup>1</sup></u> 1. Paediatric Endocrinology Unit, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium 2. Department of Genetics, Centre Hospitalier Universitaire du Sart-Tilman, Université de Liège, Liège, Belgium

We identified eight different variants predicted to be deleterious by in silico analysis in the MKRN3 gene of ten patients with iCPP from eight unrelated families.

Six of the eight pathogenic variants are novel: two of them are missense, three are nonsense and one is a frameshift variant.

In 3/8 families, we could document that the mutation was inherited from the father.

The 4 year-old twin brothers of one patient were also carriers but still prepubertal.

The ten reported patients had a very rapid pubertal development and frank LH peak after GnRH test.

Final height of affected adult relatives were within target in males but below target height in females.

studied.

# SIX NOVEL VARIANTS IN THE MKRN3 GENE CAUSING CENTRAL PRECOCIOUS PUBERTY: CHARACTERISTICS OF TEN PATIENTS AND THEIR AFFECTED RELATIVES

#### RESULTS

|                       |   | Ethnicity          | Age at                   | Age at | Tanner                |                    |     |              |     |       |               | Basal FSH /                      |                      | MKRN3 variant  |   |                                    | $\downarrow$                            | Lys359Arg   | His420Gln  |
|-----------------------|---|--------------------|--------------------------|--------|-----------------------|--------------------|-----|--------------|-----|-------|---------------|----------------------------------|----------------------|--|---|------------------------------------|---|---|--|
| Patient<br>numbe<br>r |   |                    | puberta<br>I onset,<br>y |        | stage at<br>diagnosis | diagnosi<br>s, SDS |     | - TH,<br>SDS | SDS | CA, y |               | Post-<br>stimulated<br>FSH, IU/L | ng/L<br>T,<br>nmol/L |  | C3H1<br>1 95<br>1 95<br>1<br>Pro30Leu Ile100Phe<br>Glu111*  | 122 1238<br>Gly196Val<br>Ile204Thr | C3H1 MKRN<br>CYS-HIS<br>265 266 293 311 | 365 394<br>Pro373Leu                                  | C3H1<br><sup>423</sup><br><sup>507 aa</sup><br>Arg477Gln |
| 1 / III-<br>5         | F | Caucasian          | 7.0                      | 9.0    | A2P4M4                | 1.8                | 2.3 | 0.5          | 0.7 | 3     | 20.3<br>>200  | 6.7<br>53.2                      | 170                  | c.555_556delCA, p.<br>Asp185Glufs*20<br>Frameshift                     | Arg68His Glu111* Glu183* Arg382Cys   Arg90* H148Tfs*23 Tyr246Cys Tyr391*   Asp185Glufs*20 Gly250Glu Glu256Glyfs*36   Figure 1. Structure of the MKRN3 human protein showing the location of the mutations in coding sequence from Valadares et al. in 2019 (11). The variants we report are added in red. |                                    |   |   |  |
| 2 / III-<br>8         | F | Caucasian          | 7.3                      | 7.6    | A1P1M2                | 2                  | 1.2 | /            | 0   | 1.9   | 0.1<br>9.17   | 2.1<br>14.63                     | <5                   | c.1153C>T, p.Gln385*<br>Nonsense<br>c.1235T>G, p.Phe412Cys<br>Missense | Family /  | Sex<br>F                           |   | Final Height, SDS<br>-1.5 (reported)                  | Target Height,<br>SDS<br>Unknown                         |
| 3 /<br>V-2            | F | Caucasian          | 6.4                      | 6.5    | A1P1M2                | 0.9                | 1.7 | /            | 0.5 | 1.3   | 0.8<br>15.3   | 4.5<br>10.38                     | <25                  | c.983G>A, p.Arg328His<br>Missense                                      | 1 / III-1<br>2 / I-2  | F<br>F                             | 8<br>8<br>8                             | Unknown<br>-0.6 (reported)                            | Unknown<br>Unknown                                       |
| 4 /<br>II-1           | М | Center-<br>African | ?                        | 11.7   | A3P3G4                | 0.4                | 1   | /            | 1.2 | 2     | 2.8<br>40     | 4.9<br>11.2                      | 15.7                 | c.1076A>G, p.Lys359Ar<br>Missense                                      | 2 / II-7  | F                                  | 8                                       | -2.5 (reported)                                       | -0.4   |
| 4 /<br>II-2           | F | Center-<br>African | 6.8                      | 7.2    | A2P2M2                | 1.5                | 2.1 | /            | 1.3 | 2.8   | 2.9<br>16.4   | 8.7<br>15.4                      | 45                   | c.1076A>G, p.Lys359Ar<br>Missense                                      | 2 / II-12   | Μ                                  | 9.5                                     | -0.3 (measured)                                       | -0.4   |
| 4 /<br>II-3           | F | Center-<br>African | 6.8                      | 7.2    | A1P1M2                | 0.1                | 0.7 | /            | 0   | 1.5   | <1<br>13.9    | 2.4<br>17.3                      | <25                  | c.1076A>G, p.Lys359Ar<br>Missense                                      | 2 / III-1<br>2 / III-2<br>2 / III-6   | F<br>F<br>F                        | 10<br>9<br>9.5                          | -0.6 (reported)<br>Not reached yet<br>Not reached yet | Unknown<br>Unknown<br>Unknwon                            |
| 5 / III-<br>3         | F | Caucasian          | 7.3                      | 8.3    | A1P1M3<br>-4          | 1.5                | 0.2 | 1.2          | 1.6 | 2.1   | 3.4<br>40.1   | 4.7<br>10.1                      | 29                   | c.983G>A, p.Arg328His<br>Missense                                      | 3 / IV-3<br>3 / IV-4<br>3 / IV-5  | F<br>F                             | M2 at 6<br>M2 at 7.8<br>6.5             | Unknown<br>Not reached yet<br>-2.8 (reported)         | -1<br>-1<br>-1.5   |
| 6 / IV-<br>2          | F | Caucasian          | 7                        | 8.7    | A2P3M3                | 0.9                | 0.5 | /            | 0.3 | 2.3   | 2.6<br>23.4   | 5.4<br>11.4                      | 46                   | c.268C>T, p.Arg90*<br>Nonsense   | 3 / IV-6  | M                                  | 9                                       | -1.1 (measured)                                       | -1.5   |
| 7 /<br>II-5           | F | North-<br>African  | 8.4                      | 8.7    | A2P2M3                | -0.8               | 0.3 | /            | 1.1 | 2.3   | 3.1<br>104.8  | 5.5<br>33.8                      | 12                   | c.547G>T, p.Glu183*<br>Nonsense  | 5 / I-2<br>5 / III-1  | F                                  | 9<br>9                                  | -1.6 (reported)<br>-1.5 (reported)                    | Unknown<br>-1.1  |
| 8 /<br>II-4           | F | South-<br>African  | 6                        | 6.8    | A1P1M3                | 2.7                | 2.4 | /            | 1.6 | 4.2   | 1.64<br>20.64 | 4.86<br>12.55                    | 52                   | c.982C>T, p.Arg328Cys<br>Missense                                      | 7 / II-3<br>7 / II-4  | M<br>F                             | 9-10<br>9                               | -1.6 (reported)<br>-2.8 (reported)                    | -1.3<br>-1.3   |

able 1. Clinical and Hormonal Data of the 10 Patients with CPP carrying an MKRN3 varian

## CONCLUSIONS

We report the clinical and hormonal data of ten patients with CPP due to *MKRN3* variant.

A common clinical feature seems to be the marked LH peak after GnRH test and the very rapid pubertal progression. An MKRN3 defect should be considered in all patient with CPP at a young age, rapid progression, marked LH response to GnRH or with a history of CPP in the paternal family.

The identification of an *MKRN3* variant in these patients has clinical implications:

1, it allows family segregation studies and early detection of other cases of CPP

2, it allows to avoid unnecessary CNS MRI at diagnosis Finally, iCPP seems to impact adult height in females' adult relatives carrying MKRN3 mutations unlike males, but this remains to be confirmed because only a few adults could be 2004;89(4):1794-1800 2475 gene. BMC Endocrine Disorders 2015;15:60 Endocrinol. 2016;174(1):1-8 Neuroendocrinology 2017;105(1):17-25 expression. Front Endocrinol 2019;10:48 2019;3(5):979-995 3;130(8):4486-4500

#### REFERENCES

1 de Vries L et al. Familial central precocious puberty suggests autosomal dominant inheritance. J Clin Endocrinol Metab

2 Teles MG et al., A GPR54-activating mutation in a patient with central precocious puberty. N Engl J Med 2008;358:709-715 3 Silveira LG et al. Mutations of the KISS1 gene in disorders of puberty. J Clin Endocrinol Metab 2010;95:2276-2280 4 Abreu AP et al. Central precocious puberty caused by mutations in the imprinted gene MKRN3. N Engl J Med 2013;368:2467-

5 Grandone A et al. A case of familial central precocious puberty caused by a novel mutation in the makorin RING finger protein 3

6 Simon D et al. Mutations in the maternally imprinted gene MKRN3 are common in familial central precocious puberty. Eur J

7 Bessa DS et al. High frequency of MKRN3 mutations in male central precocious puberty previously classified as idiopathic.

8 Bessa DS et al. Methylome profiling of healthy and central precocious puberty girls. *Clin Epigenetics. 2018 Nov 22;10(1):146.* 9 Jong MTC et al. A novel imprinted gene, encoding a RING zinc-finger protein, and overlapping antisense transcript in the Prader-Willi syndrome critical region. *Hum Mol Genet.* 1999;8(5):783-793

10 Yellapragada V et al. MKRN3 interacts with several proteins implicated in puberty timing but does not influence GNRH1

11 Valadares LC et al. MKRN3 mutations in central precocious puberty: a systamtic review and meta-analysis. J Endocr Soc

12 Abreu AP et al. MKRN3 inhibits the reproductive axis through actions in kisspeptin-expressing neurons. J Clin Invest. 2020 Aug

Caroline GERNAY caroline.GERNAY@huderf.be





Hôpital Universitaire des Enfants Reine Fabiola

r Kinderziekenhuis






Table 2. Clinical Data of the affected relatives of the cases

#### ACKNOWLEDGEMENTS

Thank you to all my team at HUDERF, patients and their families.

## **CONTACT INFORMATION**



Pocter. Possion

